We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC Finalizes Anticompetitive Charges Over Akorn’s Acquisition of Hi-Tech Pharmacal
FTC Finalizes Anticompetitive Charges Over Akorn’s Acquisition of Hi-Tech Pharmacal
Akorn Enterprises, or its new subsidiary Hi-Tech Pharmacal, was required to sell the marketing rights for five generic drugs to Watson Laboratories to settle federal charges that Akorn’s acquisition of Hi-Tech was anticompetitive, the FTC said.